fbpx
QQQ
+ 3.21
341.15
+ 0.93%
DIA
+ 0.69
338.09
+ 0.2%
SPY
+ 2.27
418.59
+ 0.54%
TLT
+ 0.35
142.94
+ 0.24%
GLD
-0.70
167.65
-0.42%

Video: Psychedelic Stocks With JLS Fund's Simeon Schnapper & MindMed's JR Rahn

May 13, 2021 12:11 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Video: Psychedelic Stocks With JLS Fund's Simeon Schnapper & MindMed's JR Rahn

During the Benzinga Global Small-Cap Conference on Thursday morning, psychedelics executives discussed the markets and companies' prospects.

Check out presentations by:

  • 10:30 AM – Simeon Schnapper, Managing Partner, JLS Fund
  • 11:10 AM – MindMed (NEO: MMED) (NASDAQ:MNMD) – JR Rahn, CEO & Co-Founder

Check out a highlight of MindMed's presentation:

The Benzinga Global Small-Cap Conference bridges the gap between Small-Cap companies, investors, and traders.

Learn about small-cap investing with clearly defined Educational Modules, take a look at a curated group of Small-Cap investment opportunities, and connect with the global Small-Cap audience in an intimate, virtual setting.

Missed something? Get lifetime access to the video recordings here: https://events.benzinga.com/small-cap…

Education doesn't end here. Join us next Saturday, May 22 for a FULL DAY of nonstop trading lessons at the FREE Benzinga Boot Camp: https://events.benzinga.com/boot-camp

Disclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options, and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisions.

Más contenido sobre psicodélicos en Español en El Planteo.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.


Related Articles

Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform

Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq debut on Friday. read more

Peter Thiel-Backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public

Atai Life Sciences (NASDAQ: ATAI), a biotech company in the psychedelic space, had its Nasdaq debut on Friday. read more

Psyched: Atai's $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers

Atai Launches $214 Million Nasdaq IPO Offering Psychedelics biotech platform Atai life Sciences has announced an initial public offering of approximately 14 million of its common shares, ahead of the company’s expected Nasdaq listing. read more

J.R. Rahn Steps Down As MindMed CEO

Mind Medicine Inc. (NASDAQ: MNMD), more commonly known as MindMed, has announced co-founder and chief executive J.R. Rahn is stepping down from his leadership role, effective immediately. read more